Let-7 microRNA as a potential therapeutic target with implications for immunotherapy
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: MicroRNAs (miRNA) are a class of small non-coding RNA that play a major role in various cellular processes by negatively regulating gene expression. In the past decade, miRNA dysregulation has been reported to be closely linked to inflammatory diseases. The immune response modulates cancer initiation and progression; miRNAs including let-7 family members have been shown to act as key regulators of the immune responses in various diseases and cancers. Notably, the let-7 miRNA has been reported to be closely associated with immunity, specifically with Toll-like receptors that mediate cytokine expression during pathogen infection and with the regulation of various other immune effectors. Areas covered: In this review, the authors describe the discovery of let-7 as the starting point of the RNA revolution and highlight let-7 as an efficient tool for cancer and immune therapy. Expert opinion: let-7 miRNA has emerged as a key player in cancer therapy and immune responses and it has potential role as a new immunotherapeutic target. However, while there are challenges regarding miRNA delivery, the exciting emergence of personalized medicine for cancer and immunotherapy could be beneficial for the development of let-7 therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 2×
“From that point, a variety of innovative tools for inhibition or reintroduction of miRNAs have been developed, including locked-nucleic acid (LNA)-inhibitor for various miRNA with oncogenic functions like miR-221 or miR-155 [23,24] see Rupaimoole and Slack for a review [25].”
BackgroundWightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNAs Modulate Hematopoietic Lineage Differentiation
Chen, C.-Z., Li, L., Lodish, H. F., & Bartel, D. P. (2004) · Science · doi:10.1126/science.1091903 · Cited by 3,257 · cited 1×
“ture lymphocytes supported the idea that miRNAs represent a class of molecules that regulate hematopoiesis and are important in the immune system [54].”
BackgroundTumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605 · cited 1×
“The complete comprehension of miRNA expression in disease has allowed identification of misregulation of miRNA in other sites like tumor metastases [17,18], blood circulation [19,20] and later in tumor Cancer CellDerived exosomes and the microenvironment [21].”
BackgroundThe let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells
Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., Shingara, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1083 · Cited by 1,224
Self-citationDIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions
Karagkouni, D., Paraskevopoulou, M. D., Chatzopoulos, S., Vlachos, I. S., Tastsoglou, S., Kanellos, I., Papadimitriou, D., Kavakiotis, I., Maniou, S., Skoufos, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1141 · Cited by 1,135
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 1,073 · cited 2×
“This strong evidence demonstrated a central role of miR-21 expression in tumor initiation and maintenance and confirmed the dogma of miRNA addiction in tumors [16].”
BackgroundSelf-citationExtensive post-transcriptional regulation of microRNAs and its implications for cancer
Thomson, J. M., Newman, M., Parker, J. S., Morin-Kensicki, E. M., Wright, T., & Hammond, S. M. (2006) · Genes & Development · doi:10.1101/gad.1444406 · Cited by 877
Slack, F. J., Basson, M., Liu, Z., Ambros, V., Horvitz, H. R., & Ruvkun, G. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80245-2 · Cited by 751
Self-citation
Cited by
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
Hong, W., Xue, M., Jiang, J., Zhang, Y., & Gao, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01648-1 · Cited by 342
RetractedMultilevel omics for the discovery of biomarkers and therapeutic targets for stroke
Montaner, J., Ramiro, L., Simats, A., Tiedt, S., Makris, K., Jickling, G. C., Debette, S., Sanchez, J.-C., & Bustamante, A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0350-6 · Cited by 330
miRNAs in Cancer (Review of Literature)
Smolarz, B., Durczyński, A., Romanowicz, H., Szyłło, K., & Hogendorf, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052805 · Cited by 296
let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-Like Receptor 7
Buonfiglioli, A., Efe, I. E., Guneykaya, D., Ivanov, A., Huang, Y., Orlowski, E., Krüger, C., Deisz, R. A., Markovic, D., Flüh, C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.029 · Cited by 86
Metadata
- Authors
- Gilles, M.-E., & Slack, F. J.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2018-10-17
- Volume
- 22
- Issue
- 11
- Pages
- 929-939
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2896655969
- Cited by
- 99
- References
- 12
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. https://app.cochat.ai/papers/10.1080/14728222.2018.1535594
- The paper
- Gilles, M.-E., & Slack, F. J. (2018). Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1535594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.